BridgeBio PharmaBBIO
BBIO
About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Employees: 730
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
404% more call options, than puts
Call options by funds: $389M | Put options by funds: $77.2M
39% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 36
37% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 76
15% more funds holding in top 10
Funds holding in top 10: 13 [Q3] → 15 (+2) [Q4]
11% more capital invested
Capital invested by funds: $4.36B [Q3] → $4.85B (+$484M) [Q4]
4% more funds holding
Funds holding: 250 [Q3] → 260 (+10) [Q4]
2.32% more ownership
Funds ownership: 91.16% [Q3] → 93.48% (+2.32%) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$49
28%
upside
Avg. target
$60
56%
upside
High target
$95
148%
upside
9 analyst ratings
9 positive
100%
0 neutral
0%
0 negative
0%
Scotiabank Greg Harrison 32% 1-year accuracy 13 / 41 met price target | 43%upside $55 | Sector Outperform Maintained | 30 Apr 2025 |
Piper Sandler Biren Amin 22% 1-year accuracy 6 / 27 met price target | 64%upside $63 | Overweight Maintained | 30 Apr 2025 |
UBS Eliana Merle 20% 1-year accuracy 4 / 20 met price target | 88%upside $72 | Buy Maintained | 30 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 331 met price target | 38%upside $53 | Buy Maintained | 15 Apr 2025 |
Redburn Atlantic Joshua Smith 50% 1-year accuracy 1 / 2 met price target | 30%upside $50 | Buy Initiated | 31 Mar 2025 |
Financial journalist opinion
Based on 9 articles about BBIO published over the past 30 days
Neutral
Seeking Alpha
1 day ago
BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Chinmay Shukla – Vice President-Strategic Finance Neil Kumar – Chief Executive Officer Matt Outten – Chief Commercial Officer Tom Trimarchi – President and Chief Financial Officer Ananth Sridhar – Chief Operating Officer-BridgeBio Cardiorenal Conference Call Participants Salim Syed – Mizuho Tyler Van Buren – TD Cowen Mani Foroohar – Leerink Partners Cory Kasimov – Evercore Greg Harrison – Scotiabank Paul Choi – Goldman Sachs Anupam Rama – JPMorgan Eliana Merle – UBS Jason Zemansky – Bank of America Operator Good afternoon. I will be your conference operator today.
Negative
Zacks Investment Research
1 day ago
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.05 per share a year ago.
Neutral
Investors Business Daily
1 day ago
BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations
BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market.
Neutral
GlobeNewsWire
1 day ago
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers
Neutral
GlobeNewsWire
2 days ago
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
- The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date
Neutral
PRNewsWire
1 week ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO)
NEW YORK , April 23, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating BridgeBio Pharma, Inc. (NASDAQ: BBIO) on behalf of the company's shareholders. The investigation seeks to determine whether BridgeBio Pharma's directors breached their fiduciary duties in connection with recent corporate actions.
Positive
Seeking Alpha
1 week ago
BridgeBio: Early Signs Point To Blockbuster Revenues
BridgeBio Pharma's Attruby shows strong potential in treating ATTR-CM, with a 42% reduction in mortality, competitive pricing, and convenient pill form. Early commercial launch success, high conversion rates, and channel checks suggest significant market share and revenue growth, potentially doubling current analyst estimates. BBIO's robust pipeline, favorable policy shifts, and milestone payments position it for substantial future growth, with a potential $300 price target.
Neutral
GlobeNewsWire
1 week ago
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025.
Neutral
GlobeNewsWire
2 weeks ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on April 9, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 20 new employees in restricted stock units for an aggregate of 77,652 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2026, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
Neutral
GlobeNewsWire
1 month ago
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
PALO ALTO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time to all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH) in both variant (ATTRv) and wild-type (ATTRwt) transthyretin amyloid cardiomyopathy (ATTR-CM) patients from a pre-specified subgroup analysis of ATTRibute-CM, its Phase 3 trial of acoramidis in ATTR-CM. These data were presented at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo in a poster presentation by Margot Davis, M.D. of Vancouver General Hospital, Canada. Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
Charts implemented using Lightweight Charts™